The head of South Africa's Medical Research Council (SAMRC), Glenda Gray, has said that a study has shown that Johnson and Johnson (NYSE:JNJ) COVID-19 vaccine booster shot is 85% effective in protecting against being hospitalised by the Omicron variant for one to two months after it is received, Reuters news agency reported on Friday.
The SAMRC study involved 477,234 healthcare workers, all of them vaccinated with the J&J shot, of whom 236,000, or approximately half, had received the J&J booster shot.
It looked at hospitalisations among those healthcare workers who had been infected during the fourth wave and found that the booster shot reduced hospitalisations by 63% in the first two weeks after the booster, going up to 85% after that for between one and two months.
Among the participants in the study, there were also about 30,000 breakthrough infections during the Omicron wave, compared with only around 11,000 each in the previous waves driven by the Delta and Beta variants.
In addition, the study highlighted that those infected with HIV were more vulnerable to being hospitalised with Omicron.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients